Allergan PLC said Tuesday that the Food and Drug Administration has approved Botox for the temporary improvement of moderate-to-severe forehead lines. Botox is already approved for treat “crow’s feet” and glabellar lines. Allergan’s stock, which was still inactive in premarket trade, has tumbled 13.5% over the past three months, to be up just 0.5% year to date, while the S&P 500 has gained 4.1% over the past three months and 13.0% this year.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News